P/B
0,9
Aligos Therapeutics
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
$29.8M
Market Cap • 10/23/2026
2018
(8 years)
Founded
2020
(6 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
0,9
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
5,1
EPS
—
Market Cap
Market Cap
29,8M
EV
3M
EV/Revenue
0,1
EV/EBITDA
0
EV/EBIT
0
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-1,2%
Total Yield
-1,2%
Payout
0%
Retained Earnings
-666,7M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
280,4%
Capex/Revenue
1,1%
Capex/D&A
32,9%
Capex/OCF
-0,4%
SBC/OCF
—
% PPE
5,2%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
66,6%
CAGR Op. Income 5Y
-6,9%
CAGR Net Income 5Y
-9,5%
CAGR EPS 5Y
-53,6%
CAGR OCF 5Y
1,1%
Leverage
N.D./EBITDA
0,3
Debt/Equity
0%
Current Ratio
2,2
Quick Ratio
2,1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!